You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Targeted Therapy for Breast Cancer

    SBC: A&G PHARMACEUTICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side effects and insufficient efficacy, particularly for patients with metastatic disease. Targeted cancer therapy is designed to treat only the cancer cells and minimize damage to healthy cells. These target ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. Profiling EGFR and Her2 in Breast Cancer using Multiplex Tissue Immunostaining

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new "companion" diagnostics to better select patients likely to respond to targeted therapies, including Herceptin(r) and novel tyrosine kinase inhibitors. 20/20 will utilize its proprietary layered pep ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  3. Peptide Array for Profiling of Autoantibodies in Non-small Cell Lung Cancer

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 135,000 new cases of non-small cell lung cancer (NSCLC) are diagnosed each year in the USA, yet only 20%-25% of those patients will be diagnosed at a sufficiently early stage to be cured by surgical or other procedures. When used in concert with radiographic imaging, a sensitive and specific blood test for NSCLC could be a clinically valuable and ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  4. Diagnostic protein array for respiratory infections

    SBC: AKONNI BIOSYSTEMS INC            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to transition Argonne-developed intellectual property into the commercial marketplace, and develop a protein array for clinical surveillance and diagnosis of common respiratory infections, including influenza A, influenza B, parainfluenza (types 1-3), human respiratory syncitial virus (RSV), adenovirus (types A-f), SARS coronavi ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. Integrated, on-chip RT-MME-PCR for influenza diagnostics; Phase 1 = sample prepar

    SBC: AKONNI BIOSYSTEMS INC            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza viruses are highly contagious, segmented negative-sense RNA viruses that belong to the family Orthomyxoviridae, causing approximately 114,000 hospitalizations and 20,000 deaths annually. Several drugs are approved by the US Food and Drug Administration (FDA) for treating influenza infections, but successful treatment depends on administering these dru ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  6. Treatment of diabetic gastroparesis with nitric oxide

    SBC: AMULET PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal will establish proof of concept for the use of nitric oxide (NO) as an effective treatment for diabetic gastroparesis. The NO will be delivered using Amulet's NORTECH nitric oxide releasing technology. NORTECH delivers NO in a predictable and controllable manner, and without the possibility of forming carcinogenic nitrosamines. NORTECH is uniquely ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Gestural Interfaces and Robotics for Rehabilitation

    SBC: Anthrotronix, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase II project is to develop robot-based content to target upper extremity movement therapy goals and evaluate the clinical efficacy of the CosmoBot Robotics System as a therapy intervention for children diagnosed with cerebral palsy, brain injury, and stroke. Cerebral palsy is the most prevalent and one of the three mo ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  8. The in vitro hepatitis C virus infection system as a drug discovery tool

    SBC: APATH, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection is a major cause of liver disease throughout the world. Existing therapies are suboptimal and the search for alternative therapies is imperative. Recent years have seen a tremendous increase in efforts to identify more effective therapies against HCV. These efforts have been greatly facilitated by sub-genomic HCV replicon syste ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept

    SBC: APC BIOTECHNOLOGY SERVICES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A novel bioprocess platform, involving synthesis of peptide and protein biopharmaceutical products as fusions with a synthetic "anchor" protein in bacteria, and subsequent proteolytic cleavage, will be developed. The unique features of the system allow for the economical production of large quantities of simple linear peptides, as well as complex, multi-compone ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Validation of Human Apyrase in Stroke Models

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered a human apyrase, APT1 ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government